(616 Kb) Page

: Interestingly, the most common reason for stopping the drug was toxicity (intolerance) rather than the leukemia getting worse (disease progression).

The study highlighted a few differences between "real-world" patients and those in trials: (616 KB)

Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC : Interestingly, the most common reason for stopping

Explain the specific (toxicities) that led to these discontinuations. Compare these results to more recent ibrutinib studies . (616 KB)

: For those who stopped the medication, the median time until they did so was only 7 months .

: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group.